Analisis Pelaporan Corporate Social Responsibility Pada Perusahaan Induk Dan Subsidiary Tahun 2014 (Studi Pada Perusahaan Induk Dan Subsidiary Yang Terdaftar Di Bei Dan Menggunakan Pedoman Gri G4)

The purposes of this research are to know the corporate social responsibility (CSR) reporting for parent and subsidiary companies that used GRI G4 and also to know the difference of their CSR reporting. This research used case study with qualitative approach. The focus of this research is the content of CSR for parent and subsidiary companies that using GRI G4 in the year 2014. Indicators in the General and Specific standard disclosures of GRI G4 are also analyzed in this study. This research found that CSR reporting for parent and subsidiary companies is suitable with GRI G4. This can be seen from the companies\u27 reporting which already appropriate with materiality value. This research also shows that there is no significant difference of CSR reporting between parent and subsidiary companies. There is also no material difference about the number of indicators which reported among parent and subsidiary companies. Additionally, the parent and subsidiary companies reported the same indicators, although there are several difference aspects. The parent and subsidiary companies in this research also use the same standard, that is core standard

Using GPS technologies with People with Dementia: A synthesising review and recommendations for future practice

In Norway and other Nordic countries, there is a policy emphasis on using welfare technologies to support people to live at home. For example, Global Positioning Systems (GPS) or ‘location technologies’ are used to support people with dementia and their next of kin with wayfinding. However, the research evidence has not been synthesised, and so the opportunities and challenges presented when using GPS technologies are not clear. This synthesising review examined all available empirical evidence on the use of GPS technologies by people with dementia and their family carers, through a critical disability lens – that is, in terms of protecting a person’s right to live in the community and taking the standpoint of the person with dementia (rather than a caregiver or health professional). Employing this lens meant that we engaged with the literature in a more critical way than standard reviews, and consciously looked for evidence of marginalisation. A search of six major English language databases in 2016 identified 23 studies that met the inclusion criteria. Synthesis of the findings led to the identification of three overarching themes: using GPS to stay safe, taking control and the value of GPS data for researchers. The review revealed a growing interest in the use of GPS technologies by people with dementia, which indicates that policy implementation is effective. Future work should take a disability-rights approach and focus on the value of using GPS technologies from the perspective of the person with dementia, as the opinions of this group are often overlooked in discussions about welfare technologies

The effects of postmenopausal hormone therapy on social activity, partner relationship, and sexual life – experience from the EPHT trial

<p>Abstract</p> <p>Background</p> <p>With the exception of sexual functioning and weight, social and behavioural effects of postmenopausal hormone therapy (HT) have not been reported from trials. This paper reports such results from the EPHT-trial in Estonia.</p> <p>Methods</p> <p>A randomized trial, with a blind and non-blind sub-trial in Estonia. From 1999–2001, 1778 women were recruited. The mean follow-up was 3.6 years. Women's experiences were asked in the first and final study year by mailed questionnaires (74 and 81% response rates). Comparisons of the groups were made by cross-tabulation and logistic regression, adjusting for age.</p> <p>Results</p> <p>There were no differences between the HT and non-HT groups in regard to being employed, the extent of social involvement or marital status or opinions on aging. There was no difference in the frequency of free-time exercise, or overweight. Some of the indicators suggested less sexual inactivity, but the differences were small.</p> <p>Conclusion</p> <p>In a trial setting, postmenopausal hormone therapy did not influence work or social involvement or health behaviour.</p> <p>Trial registration</p> <p>ISRCTN35338757</p

Surveillance Technology in Dementia Care: Implicit Assumptions and Unresolved Tensions

This paper examines the concept of “Surveillance Technology [ST]” as it is used in ageing and dementia research but which suffers from poor definition. We attempt to clarify this imprecision by contextualizing a brief history of the development of ST and provide a summary of the research in this area. We contrast this with the responses provided by a public and patient involvement group of people living with a dementia diagnosis, or experience of supporting people with dementia. ST operates in multiple interacting ways, all of which need to be taken into account in research, public and policy debate. As a technology it is often seen as a way of assisting individuals and therefore classified as an Assistive Technology [AT]. However, the meaning of ST used in dementia care has pragmatic implications beyond the meeting of the needs for “safety and independence”; ideas which is often used to justify its use. We argue that there is need to interrogate the terms “Surveillance” and “Technology” more carefully if ST is to be considered as empowering for people with dementia. This tension is brought out in the accounts present in a group discussion on ST and its use. This paper argues that there needs to be an acknowledgement that the purposes of such technologies need to be regularly reviewed in order for society to keep up with the rapidly changing pace of technology and the changing needs of users

Experiences of a long-term randomized controlled prevention trial in a maiden environment: Estonian Postmenopausal Hormone Therapy trial

<p>Abstract</p> <p>Background</p> <p>Preventive drugs require long-term trials to show their effectiveness or harms and often a lot of changes occur during post-marketing studies. The purpose of this article is to describe the research process in a long-term randomized controlled trial and discuss the impact and consequences of changes in the research environment.</p> <p>Methods</p> <p>The Estonian Postmenopausal Hormone Therapy trial (EPHT), originally planned to continue for five years, was planned in co-operation with the Women's International Study of Long-Duration Oestrogen after Menopause (WISDOM) in the UK. In addition to health outcomes, EPHT was specifically designed to study the impact of postmenopausal hormone therapy (HT) on health services utilization.</p> <p>Results</p> <p>After EPHT recruited in 1999–2001 the Women's Health Initiative (WHI) in the USA decided to stop the estrogen-progestin trial after a mean of 5.2 years in July 2002 because of increased risk of breast cancer and later in 2004 the estrogen-only trial because HT increased the risk of stroke, decreased the risk of hip fracture, and did not affect coronary heart disease incidence. WISDOM was halted in autumn 2002. These decisions had a major influence on EPHT.</p> <p>Conclusion</p> <p>Changes in Estonian society challenged EPHT to find a balance between the needs of achieving responses to the trial aims with a limited budget and simultaneously maintaining the safety of trial participants. Flexibility was the main key for success. Rapid changes are not limited only to transiting societies but are true also in developed countries and the risk must be included in planning all long-term trials.</p> <p>The role of ethical and data monitoring committees in situations with emerging new data from other studies needs specification. Longer funding for preventive trials and more flexibility in budgeting are mandatory. Who should prove the effectiveness of an (old) drug for a new preventive indication? In preventive drug trials companies may donate drugs but they take a financial risk, especially with licensed drugs. Public funding is crucial to avoid commercial biases. Legislation to share the costs of large post-marketing trials as well as regulation of manufacturer's participation is needed. [ISRCTN35338757]</p

Use of the physical environment to support everyday activities for people with dementia: A systematic review

Difficulty with everyday activities is a key symptom and defining feature of dementia, relating to subjective reports of well-being and overall quality of life. One way to support individuals in their daily activities is by modifying the physical environment to make it easier to interact with during activity performance. This systematic review explores the range of studies available using physical environmental strategies to support performance in everyday activities for people with dementia. Seventy-two relevant studies were identified by the search. Physical environmental strategies included changes to the global environment and to architectural features, use of moveable environmental aids and tailored individual approaches. Strategies supported general everyday activity functioning (N = 19), as well as specific activities, particularly mealtimes (N = 15) and orientation in space (N = 16); however, few studies were found that focused on aspects of personal care such as dressing (N = 1) and showering or the preferred hobbies of individuals (N = 0). Overall, there appeared to be a lack of research within private home environments, and of studies which specify the dementia syndrome or the whole neuropsychological profile of people with dementia. More work is needed to extend theoretical understandings of how people with dementia interact with their environments so that these spaces can be designed to further support activities of daily living performance. Future work in this field could also incorporate the perspectives and preferences of those living with dementia.The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This review was supported by a studentship from Brunel University London. The studentship is attached to a grant from the ESRC-NIHR (UK) (Grant ES/L001810/1). Grant title: Seeing what they see: compensating for cortical visual dysfunction in Alzheimer’s Disease. SC is also supported by the NIHR Queen Square Dementia Biomedical Research Unit and an Alzheimer’s Research UK Senior Research Fellowship

Cognitive aids for people with early stage dementia versus treatment as usual (Dementia Early Stage Cognitive Aids New Trial (DESCANT)): study protocol for a randomised controlled trial

Background: There is a growing need for an evidence-based approach to home support for people with dementia and their carers following diagnosis but research on the effectiveness and cost-effectiveness of different approaches is sparse. The Dementia Early Stage Cognitive Aids New Trial (DESCANT) will evaluate the clinical and costeffectiveness of a range of memory aids, training and support to people with mild to moderate dementia and their carers at home and compares that intervention with treatment as usual.Methods/design: This is a multi-site, pragmatic randomised trial preceded by a feasibility study and internal pilot. We aim to allocate at random 360 pairs comprising a person with mild to moderate dementia and an identified carer between the DESCANT intervention and treatment as usual. We assess participants at baseline, 13 and 26 weeks. The primary outcome measure is the Bristol Activities of Daily Living Scale; other participant outcomes include cognition, quality of life, activities of daily living and social networking; carer outcomes include quality of life, sense of competence and mental health. To enhance this quantitative evaluation we are conducting a qualitative component and a process evaluation to assess the implementation process and identify contextual factors associated with variation.Discussion: The DESCANT intervention reflects current policy to enhance the capabilities of people with dementia after diagnosis and their carers. If it is clinically and cost-effective, its modest nature and cost will enhance the likelihood of it being incorporated into mainstream practice.Trial registration: Current Controlled Trials, ISRCTN12591717. Registered on 29 July 2016.Protocol number: 31288: North West - Haydock Research Ethics Committee, 20/06/2016, ref.: 16/NW/0389